cp-547632 and Hemangiosarcoma

cp-547632 has been researched along with Hemangiosarcoma* in 1 studies

Other Studies

1 other study(ies) available for cp-547632 and Hemangiosarcoma

Article	Year
Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases. Bioorganic & medicinal chemistry letters, 2008, Mar-15, Volume: 18, Issue:6 Fused dihydroindazolopyrrolocarbazole oximes have been identified as low nanomolar, potent dual TIE-2 and VEGF-R2 receptor tyrosine kinase inhibitors with excellent cellular potency. Development of the structure-activity relationships (SAR) led to identification of compounds 35 and 40 as potent, selective dual TIE-2/VEGF-R2 inhibitors with favorable pharmacokinetic properties. Compound 35 was orally active in tumor models with no observed toxicity. Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Cell Proliferation; Cells, Cultured; Drug Design; Endothelium, Vascular; Hemangiosarcoma; Humans; Melanoma, Experimental; Molecular Structure; Neovascularization, Pathologic; Oximes; Protein Kinase Inhibitors; Rats; Receptor, TIE-2; Structure-Activity Relationship; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-2	2008

Article

Year

Design and synthesis of dihydroindazolo[5,4-a]pyrrolo[3,4-c]carbazole oximes as potent dual inhibitors of TIE-2 and VEGF-R2 receptor tyrosine kinases.

Bioorganic & medicinal chemistry letters, 2008, Mar-15, Volume: 18, Issue:6

Fused dihydroindazolopyrrolocarbazole oximes have been identified as low nanomolar, potent dual TIE-2 and VEGF-R2 receptor tyrosine kinase inhibitors with excellent cellular potency. Development of the structure-activity relationships (SAR) led to identification of compounds 35 and 40 as potent, selective dual TIE-2/VEGF-R2 inhibitors with favorable pharmacokinetic properties. Compound 35 was orally active in tumor models with no observed toxicity.

Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Cell Proliferation; Cells, Cultured; Drug Design; Endothelium, Vascular; Hemangiosarcoma; Humans; Melanoma, Experimental; Molecular Structure; Neovascularization, Pathologic; Oximes; Protein Kinase Inhibitors; Rats; Receptor, TIE-2; Structure-Activity Relationship; Umbilical Veins; Vascular Endothelial Growth Factor Receptor-2

2008